Pennington Biomedical Research Center Receives FDA Approval to Begin Phase I Studies of Compellis Pharmaceuticals’ Novel and Patented Obesity Therapy

BOSTON, MA--(Marketwire - January 08, 2008) - Compellis Pharmaceuticals, an early stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that its collaborator Pennington Biomedical Research Institute at Louisiana State University, with Principal Investigator Dr. Frank Greenway, MD, has received FDA approval to begin human clinical Phase I studies. Enrollment for the program will begin in the first quarter of 2008 with an expected completion date in the second half of the year.